Hermetica Superfood Encyclopedia
The Short Answer
Ecklonia cava contains a distinct class of marine polyphenols called phlorotannins—including dieckol, eckol, phlorofucofuroeckol A, and 8,8'-bieckol—which exert antioxidant, anti-inflammatory, and lipid-lowering effects by activating Nrf2/HO-1 cytoprotective pathways, suppressing NLRP3 inflammasome and NFκB signaling, and downregulating hepatic lipogenic proteins SREBP1c, ACC, and FAS. In high-fat diet-induced obese mouse models, a polyphenol-rich Ecklonia cava fraction (G-CA) significantly reduced serum ALT from 60.25 ± 3.00 U/L to 32.45 ± 4.92 U/L (p<0.01), alongside improvements in glucose and obesity markers, though no human clinical trials have yet replicated these findings.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordEcklonia cava phlorotannins benefits
Ecklonia cava Phlorotannins — botanical close-up
Health Benefits
**Antioxidant Defense Upregulation**
Phlorotannins—particularly dieckol and eckol—activate the Nrf2/HO-1/NQO1 transcriptional axis, increasing endogenous antioxidant enzymes (MnSOD, GPx) and reducing oxidative damage markers such as 4-hydroxynonenal (4-HNE) and protein carbonyls in preclinical models.
**Anti-Inflammatory Activity**
Ecklonia cava extracts suppress NLRP3 inflammasome activation and downregulate NFκB-driven cytokine production (TNF-α, MCP-1, CRP), reducing systemic and tissue-level inflammation in high-fat diet rodent models at doses of 100–500 mg/kg/day.
**Hepatic Lipid Accumulation Reduction**
By lowering protein expression of the lipogenic transcription factor SREBP1c and downstream enzymes ACC and FAS, Ecklonia cava polyphenol extract (ECPE) attenuates hepatic fat deposition, with ALT normalization observed in obese mouse models (ALT reduction from ~60 to ~32 U/L).
**Metabolic and Glycemic Modulation**
Polyphenol-rich fractions (G-CA) have demonstrated reductions in fasting blood glucose and obesity-associated metabolic markers in high-fat diet-induced mouse models over 12-week intervention periods, suggesting potential insulin-sensitizing activity via gene expression changes in adipogenesis pathways.
**Renal Lipotoxicity Protection**
ECPE (100–500 mg/kg/day, 12 weeks) reduced renal fat accumulation and oxidative stress markers in obese rodents, paralleling hepatic protective effects, likely through shared Nrf2 and NFκB pathway modulation.
**Unique Phlorotannin Bioavailability**
Intravenous pharmacokinetic studies in rats demonstrate prolonged plasma presence for dieckol (C₀ = 8,890 ng/mL, detectable to 36h, Vz = 3,350 mL/kg) and 8,8'-bieckol (C₀ = 7,220 ng/mL), indicating tissue distribution potential, though oral bioavailability data remain limited.
**Anti-Aging Oxidative Stress Mitigation**
By reducing chronic oxidative burden through dual radical-scavenging and enzyme-induction mechanisms, Ecklonia cava phlorotannins are studied for their potential to slow age-associated cellular oxidative damage, though human evidence for this application is currently absent.
Origin & History
Natural habitat
Ecklonia cava is a perennial brown macroalga (Phaeophyceae) endemic to the temperate coastal waters of East Asia, particularly the subtidal zones of Japan, Korea, and China, where it grows anchored to rocky substrates at depths of 1–10 meters. It thrives in nutrient-rich, cool-to-moderate seawater and is commercially harvested primarily along the southern Korean coastline and Japanese islands, where seasonal variation in water temperature and light exposure influences phlorotannin biosynthesis. Unlike terrestrial plant polyphenols, its bioactive phenolic compounds—phlorotannins—are biosynthesized exclusively within brown algae via a unique polyketide pathway, with no equivalent compounds found in land plants.
“Ecklonia cava lacks a documented history of targeted medicinal use in formal traditional East Asian pharmacopeias such as the Chinese Materia Medica (Bencao Gangmu) or Korean traditional medicine (Hanbang), though brown seaweeds broadly have been consumed as food in coastal Korean and Japanese communities for centuries. In Korean coastal cuisine, Ecklonia cava and related kelp species have been incorporated into dietary staples such as soups and side dishes (namul), where incidental phlorotannin consumption would have occurred without pharmacological intent. The systematic investigation of Ecklonia cava as a source of bioactive polyphenols is an entirely modern scientific endeavor, emerging primarily from Korean and Japanese marine biotechnology research programs beginning in the late 20th century, with significant extraction chemistry and bioactivity characterization work published from the 2000s onward. No historical ethnobotanical records document its use for antioxidant, anti-aging, or metabolic indications specifically, distinguishing it sharply from terrestrial medicinal herbs with centuries-long therapeutic traditions.”Traditional Medicine
Scientific Research
The totality of available evidence for Ecklonia cava phlorotannins is preclinical, derived exclusively from in vitro cell-based assays and in vivo rodent models—no peer-reviewed human randomized controlled trials with specified sample sizes or validated effect sizes have been published as of the current evidence review. Rodent intervention studies employing high-fat diet-induced obesity models demonstrate statistically significant reductions in hepatic enzyme markers (ALT: 60.25 ± 3.00 vs. 32.45 ± 4.92 U/L, p<0.01), lipogenic protein expression, and inflammatory biomarkers at ECPE doses of 100–500 mg/kg/day over 12-week periods, with gene expression changes confirmed by qPCR using the ΔΔCt quantification method. Pharmacokinetic characterization in rats (IV administration, EK-ECP fraction) provides rigorous compound-level data for dieckol, 8,8'-bieckol, and PFF-A, including volume of distribution and clearance rates, lending mechanistic plausibility but not translational confirmation. The evidence base is analytically rigorous in its extraction chemistry and biomarker quantification but remains fundamentally limited by the absence of human trials, undefined rodent group sizes in several studies, and unresolved oral bioavailability data, warranting a conservative interpretation of efficacy claims.
Preparation & Dosage
Traditional preparation
**Methanol/Ethyl Acetate Extract (Research Standard)**
70 mg total polyphenols per gram
Produced by refluxing dried, powdered Ecklonia cava in methanol (3 hours), followed by liquid-liquid partitioning with CH₂Cl₂/H₂O and sequential n-hexane/85% aqueous ethanol fractionation; yields ethyl acetate fractions containing 68.78–79..
**Polyphenol-Rich Powder (ECPE/EK-ECP)**
100–500 mg/kg/day—no validated human dose equivalent established
Standardized to phlorotannin content confirmed by Folin-Ciocalteu assay (up to 91% phlorotannins in some preparations); used in rodent studies at .
**Human Dose Extrapolation (Preclinical)**
100–500 mg/kg/day would approximate 570–2,900 mg/day in a 60 kg adult, but this extrapolation is unvalidated and should not be used as a clinical recommendation
Applying standard body surface area conversion (Km factor 6.2 for humans vs. 3 for mice), the rodent effective dose of .
**HPLC-Isolated Phlorotannin Standards**
Individual compounds (dieckol, eckol, PFF-A, 8,8'-bieckol) isolated via preparative HPLC for research purposes; not yet available as standardized consumer supplement ingredients.
**Whole Algae Powder**
The least processed form; phlorotannin content varies significantly by harvest location, season, and drying method; no standardization benchmarks established for commercial products.
**Timing**
No human pharmacodynamic timing data available; IV rat pharmacokinetics show dieckol detectable to 36 hours post-dose, suggesting potential for once-daily oral dosing if oral bioavailability is confirmed.
Nutritional Profile
Ecklonia cava as a whole alga provides dietary fiber (including bioactive polysaccharides such as fucoidan and laminarin), trace minerals (iodine, calcium, magnesium, iron), and small amounts of protein and omega-3 fatty acids typical of brown macroalgae, though precise macronutrient concentrations vary by harvest conditions and processing. Its primary pharmacologically relevant phytochemical profile is dominated by phlorotannins at 68.78–79.70 mg/g in polyphenol-rich ethyl acetate extracts, with individual compound concentrations including dieckol (16.56 mg/g), eckol (12.98 mg/g), and eckstolonol (12.78 mg/g) in cold acetone (CA) fractions. Bioavailability of phlorotannins is mechanistically plausible given their confirmed plasma presence in rat IV studies (dieckol Vz = 3,350 mL/kg, indicating tissue distribution), but oral bioavailability is poorly characterized due to likely first-pass metabolism, gut microbiome biotransformation, and the high molecular weight of oligomeric phlorotannins. PFF-A demonstrates rapid systemic clearance (Cl = 84,000 mL/h/kg IV), contrasting sharply with dieckol (Cl = 193 mL/h/kg) and 8,8'-bieckol (Cl = 162 mL/h/kg), indicating compound-specific bioavailability profiles that complicate standardization of extract-based supplements.
How It Works
Mechanism of Action
Ecklonia cava phlorotannins—structurally phloroglucinol-based oligomers confirmed by ¹H-NMR with aromatic resonances at 5.5–6.5 ppm and phenolic hydroxyl signals at 8.5–9.7 ppm—exert antioxidant effects through two complementary mechanisms: direct free radical scavenging via their polyhydroxylated aromatic rings, and transcriptional upregulation of the Nrf2/Keap1 pathway, leading to increased expression of HO-1, NQO1, MnSOD, and GPx, which collectively reduce 4-HNE adduct formation and protein carbonylation. Anti-inflammatory activity is mediated by inhibition of NLRP3 inflammasome assembly and suppression of NFκB nuclear translocation, resulting in downregulated transcription of pro-inflammatory mediators including TNF-α, MCP-1, and CRP. Lipid metabolism regulation occurs through reduced protein expression of the master lipogenic transcription factor SREBP1c and its downstream targets acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), thereby curtailing de novo lipogenesis in hepatic and renal tissues. Compound-specific activity varies: dieckol (16.56 mg/g in ethyl acetate fractions) and PFF-A are particularly potent in low-polarity bioassay systems, while 8,8'-bieckol exhibits distinct high-polarity chromatographic behavior and differential clearance kinetics (Cl = 162 mL/h/kg IV in rats).
Clinical Evidence
No human clinical trials investigating Ecklonia cava phlorotannins with defined sample sizes, control arms, or validated clinical endpoints have been identified in the current evidence review. Available intervention data originate from high-fat diet-induced obese mouse models treated with polyphenol-rich fractions (G-CA, ECPE) at doses of 100–500 mg/kg/day for up to 12 weeks, measuring outcomes including serum ALT, fasting glucose, lipogenic protein expression (SREBP1c, ACC, FAS), and inflammatory markers (NLRP3, NFκB, TNF-α, CRP). The most quantified outcome—ALT reduction from 60.25 ± 3.00 to 32.45 ± 4.92 U/L (p<0.01) with G-CA treatment—represents a statistically meaningful hepatoprotective signal but cannot be extrapolated to human dosing or efficacy without bridging pharmacokinetic and clinical studies. Confidence in translational clinical benefit is currently low; Ecklonia cava phlorotannins represent a scientifically promising but clinically unvalidated ingredient requiring well-designed Phase I/II human trials to establish safety, effective human dosing, and measurable clinical outcomes.
Safety & Interactions
No human safety data, adverse event reports, or clinical toxicology studies for Ecklonia cava phlorotannin extracts are available in the published literature; rodent studies at doses of 100–500 mg/kg/day over 12 weeks report no observed toxicity, with metabolic biomarkers improving rather than deteriorating, but this does not constitute a validated human safety profile. No drug interaction studies have been conducted; given the documented NFκB and Nrf2 pathway modulation, theoretical interactions with immunosuppressants (e.g., corticosteroids, calcineurin inhibitors), anticoagulants (given polyphenol effects on platelet aggregation), and cytochrome P450-metabolized pharmaceuticals cannot be excluded but remain speculative. No contraindications are established; however, individuals with thyroid conditions should exercise caution given the iodine content of whole algae preparations, and those on anticoagulant therapy (warfarin, direct oral anticoagulants) should consult a healthcare provider before use given the polyphenol class's potential platelet-modulating properties. Pregnancy and lactation safety is entirely undetermined; in the absence of any human exposure data, use during pregnancy or breastfeeding cannot be recommended, and no maximum safe human dose has been established by any regulatory or clinical authority.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Phlorotannins from Ecklonia cava (Ecklonia cava, brown seaweed)Kelp polyphenolsPhlorotannins from brown algaeECPE (Ecklonia cava polyphenol extract)EK-ECPGol-pae (Korean)Ecklonia cava
Frequently Asked Questions
What are phlorotannins in Ecklonia cava and how are they different from regular polyphenols?
Phlorotannins are a class of polyphenols found exclusively in brown algae like Ecklonia cava, biosynthesized from phloroglucinol units via a marine polyketide pathway—a route with no equivalent in terrestrial plants. Unlike plant tannins derived from gallic acid or flavan-3-ol units, Ecklonia cava phlorotannins (including dieckol, eckol, PFF-A, and 8,8'-bieckol) are structurally unique polyhydroxylated aromatic oligomers confirmed by ¹H-NMR, giving them distinct antioxidant and anti-inflammatory properties not found in land-plant polyphenol sources.
Is there any human clinical trial evidence for Ecklonia cava polyphenol supplements?
As of the current evidence review, no peer-reviewed human clinical trials with defined sample sizes, randomized control arms, or validated clinical endpoints have been published for Ecklonia cava phlorotannin extracts. All efficacy data originate from high-fat diet-induced rodent models and in vitro cell studies, where outcomes like ALT reduction (from ~60 to ~32 U/L, p<0.01) and lipogenic protein suppression have been demonstrated at 100–500 mg/kg/day doses. Human trials are needed before any clinical efficacy claims can be substantiated.
What is the recommended dosage of Ecklonia cava extract for humans?
No standardized or clinically validated human dose for Ecklonia cava phlorotannin extracts has been established. Rodent studies use 100–500 mg/kg/day of polyphenol-rich extract, which using allometric body surface area scaling would theoretically approximate 570–2,900 mg/day for a 60 kg adult—but this extrapolation is not validated and should not be treated as a clinical recommendation. Until human pharmacokinetic and dose-finding trials are completed, no evidence-based dosage guidance can be provided.
Are Ecklonia cava supplements safe to take daily?
Rodent studies at 100–500 mg/kg/day over 12 weeks have not reported observable toxicity, with metabolic markers improving during treatment, but this does not constitute validated human safety data. No human adverse event data, drug interaction studies, or maximum safe dose determinations exist for Ecklonia cava phlorotannin extracts. Individuals taking anticoagulants, immunosuppressants, or thyroid medications, as well as pregnant or breastfeeding individuals, should avoid use until human safety studies are available.
Which specific compounds in Ecklonia cava are responsible for its antioxidant effects?
The primary antioxidant-active phlorotannins in Ecklonia cava are dieckol (16.56 mg/g in ethyl acetate fractions), eckol (12.98 mg/g), eckstolonol (12.78 mg/g), phlorofucofuroeckol A (PFF-A), and 8,8'-bieckol (1.79 mg/g). These compounds exert antioxidant activity through two mechanisms: direct radical scavenging via their polyhydroxylated aromatic ring systems, and indirect upregulation of endogenous antioxidant enzymes (MnSOD, GPx, HO-1, NQO1) through transcriptional activation of the Nrf2/Keap1 pathway, reducing biomarkers of oxidative damage including 4-HNE and protein carbonyls in preclinical models.
How does Ecklonia cava polyphenol compare to other brown algae extracts for antioxidant protection?
Ecklonia cava is particularly rich in phlorotannins like dieckol and eckol, which are more potent Nrf2 pathway activators than polyphenols found in other brown algae species such as Undaria pinnatifida or Saccharina japonica. These unique compounds upregulate endogenous antioxidant enzymes (MnSOD, GPx) more effectively in preclinical models, making Ecklonia cava extracts notably superior for cellular antioxidant defense. The concentration and bioactivity of phlorotannins varies significantly between brown algae species and harvest conditions.
Does Ecklonia cava polyphenol interact with blood pressure medications or anticoagulants?
While Ecklonia cava extracts have shown anti-inflammatory effects via NLRP3 inflammasome suppression in preclinical studies, there is limited human clinical data on interactions with common cardiovascular medications such as ACE inhibitors, beta-blockers, or warfarin. Individuals taking prescription blood pressure or anticoagulant medications should consult a healthcare provider before supplementing, as polyphenols may potentiate anticoagulant effects or affect medication metabolism. No serious adverse interaction reports exist in the current literature, but clinical evidence is insufficient for definitive safety clearance.
Who would benefit most from Ecklonia cava polyphenol supplementation based on current research?
Individuals with elevated oxidative stress biomarkers (such as increased 4-hydroxynonenal or protein carbonyls) or chronic inflammatory conditions may theoretically benefit most, as Ecklonia cava's phlorotannins upregulate the Nrf2/HO-1/NQO1 antioxidant pathway and suppress NLRP3 inflammasome activation in cell models. However, because human clinical trials in Ecklonia cava remain limited, current evidence is strongest for populations studied in preclinical research rather than defined patient groups. Individuals seeking preventive antioxidant support without existing inflammatory or metabolic disease lack robust clinical evidence for specific benefit.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w polyphenol-ecklonia-cava-brown-algae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
